MedCity News August 12, 2024
Merck is acquiring a Curon Biopharmaceuticals drug whose encouraging Phase 1 data were presented during the ASCO annual meeting. The pharmaceutical giant sees potential applications of the bispecific antibody in cancer and autoimmune disease.
Antibody drugs that go after two targets have already made their mark in blood cancers, but the field is working to improve on the safety and efficacy of this approach. Merck is getting a contender from Curon Biopharmaceutical that could have applications in both oncology and immunology.
Merck is paying $700 million up front for global rights to Curon’s CN201, a bispecific antibody in early-stage clinical development, the company announced Friday. Curon could receive up to $600 million in milestone payments tied to the development and...
Today's Sponsors
Today's Sponsor